Research and Markets (http://www.researchandmarkets.com/research/26a2a4/systemic_fungal_in) has announced the addition of Frost & Sullivan's new report "Systemic Fungal Infection Therapeutics Market India" to their offering.
“The task is made easier for physicians with the growing availability of non-microbiologic and clinical diagnostic techniques, such as Platelia, Fungitell and PNA FISH, to identify the onset of infection.”
This Frost & Sullivan research service titled Systemic Fungal Infection Therapeutics Market India provides an analysis of the current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. This study is aimed at supporting manufacturers in decision making in identifying and prioritizing opportunities in India.
Market Overview
Advances in Diagnostic Tests Expand Possibilities for a More Targeted Approach to Treatment of Systemic Fungal Infections
With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFIs) is expected to increase steadily over the next five years. Alongside this development, a high premium on products that are capable of tackling emergent, problematic pathogens will also contribute to changing market dynamics. Estimates reveal that the global prevalence of SFI has risen to 4 for every 1,000 of the global population. The high incidence of SFI over the years is attributed to the widespread use of broadspectrum antibiotics, which reduce nonpathogenic bacterial populations that compete with fungi, and the growing number of persons with compromised immune systems caused by acquired immunodeficiency syndrome (AIDS), immunosuppressant drugs, and chemotherapy agents. "Early diagnosis of systemic fungal infections has been shown to be critical to treatment outcome," notes the analyst of this research service. "Advances in diagnostic capabilities are paving the way for more increased usage of targeted therapy for systemic fungal infections; this is reflected in the growing proportion of patients treated definitively in the last five years."